These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2988227)

  • 1. Bluetongue vaccine: cells and/or antibodies.
    Jeggo MH; Wardley RC
    Vaccine; 1985 Mar; 3(1):57-8. PubMed ID: 2988227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potency and efficacy of inactivated bluetongue virus vaccines.
    Stevens DR; Stott J; Osburn BI; Giles R; Wiesehahn GP; Barber TL
    Prog Clin Biol Res; 1985; 178():649-52. PubMed ID: 2989914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and serological response of sheep to serial challenge with different bluetongue virus types.
    Jeggo MH; Gumm ID; Taylor WP
    Res Vet Sci; 1983 Mar; 34(2):205-11. PubMed ID: 6304836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory evaluation of a living attenuated vaccine against bluetongue type 20 virus.
    Wark MC; Shepherd-Clark MB; Smith HV; Collins WD
    Aust Vet J; 1982 Jul; 59(1):6-10. PubMed ID: 6293439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunobiology of bluetongue virus.
    Schultz KT; Grieder FB
    Vet Immunol Immunopathol; 1987 May; 15(1-2):115-27. PubMed ID: 3039718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of a quadrivalent modified-live bluetongue virus vaccine in wildlife species.
    McConnell S; Morrill JC; Livingston CW
    Prog Clin Biol Res; 1985; 178():631-8. PubMed ID: 2989912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic response of sheep to inactivated and virulent bluetongue virus.
    Stott JL; Barber TL; Osburn BI
    Am J Vet Res; 1985 May; 46(5):1043-9. PubMed ID: 2988376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the humoral response between sheep vaccinated with a killed-virus vaccine and those vaccinated with a modified-live virus vaccine against bluetongue virus serotype 17.
    Speiser KL; Schumaker BA; Cook WE; Cornish TE; Cammack KM; Miller MM
    J Am Vet Med Assoc; 2016 May; 248(9):1043-9. PubMed ID: 27074613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of neutralising antibody in passive immunity to bluetongue infection.
    Jeggo MH; Wardley RC; Taylor WP
    Res Vet Sci; 1984 Jan; 36(1):81-6. PubMed ID: 6324311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune response to bluetongue virus infection.
    Stott JL; Osburn BI
    Curr Top Microbiol Immunol; 1990; 162():163-78. PubMed ID: 2166645
    [No Abstract]   [Full Text] [Related]  

  • 11. Inactivated bluetongue virus vaccine in lambs: differential serological responses related to breed.
    Berry LJ; Osburn BI; Stott JL; Farver T; Heron B; Patton W
    Vet Res Commun; 1982 May; 5(3):289-93. PubMed ID: 6287706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An experimental inactivated vaccine against bluetongue.
    Parker J; Herniman KA; Gibbs EP; Sellers RF
    Vet Rec; 1975 Mar; 96(13):284-7. PubMed ID: 165609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serial inoculation of sheep with two bluetongue virus types.
    Jeggo MH; Wardley RC; Brownlie J; Corteyn AH
    Res Vet Sci; 1986 May; 40(3):386-92. PubMed ID: 3016851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production of murine cytotoxic T lymphocytes by bluetongue virus following various immunisation procedures.
    Jeggo MH; Wardley RC
    Res Vet Sci; 1982 Sep; 33(2):212-5. PubMed ID: 6293026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The current status of research on an experimental inactivated bluetongue virus vaccine.
    Stott JL; Osburn BI; Barber TL
    Proc Annu Meet U S Anim Health Assoc; 1979; (83):55-62. PubMed ID: 233389
    [No Abstract]   [Full Text] [Related]  

  • 16. The use of recombinant DNA technology for the development of a bluetongue virus subunit vaccine.
    Huismans H
    Onderstepoort J Vet Res; 1985 Sep; 52(3):149-51. PubMed ID: 3003649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-propiolactone inactivated bivalent bluetongue virus vaccine containing Montanide ISA-71VG adjuvant induces long-term immune response in sheep against serotypes 4 and 16 even after 3 years of controlled vaccine storage.
    Zhugunissov K; Bulatov Y; Taranov D; Yershebulov Z; Koshemetov Z; Zhunushov A; Renukaradhya GJ; Tabynov K; Abduraimov Y
    Vet Microbiol; 2018 Nov; 226():23-30. PubMed ID: 30389040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralising antibody responses in cattle and sheep following booster vaccination with two commercial inactivated bluetongue virus serotype 8 vaccines.
    Bartram DJ; Heasman L; Batten CA; Oura CA; Plana-Durán J; Yuen HM; Wylie AD
    Vet J; 2011 May; 188(2):193-6. PubMed ID: 20466568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of ovine cytotoxic T cells in protection against bluetongue virus infection.
    Jeggo MH; Wardley RC; Brownlie J
    Prog Clin Biol Res; 1985; 178():477-87. PubMed ID: 2989889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the immune response afforded by a subunit vaccine candidate against bluetongue virus in mice and sheep.
    Mohamed DKA; Du J; Gao S; Tian Z; Zhang G; Huang D; Du R; Kang B; Liu G; Luo J; Yin H
    Vet Microbiol; 2018 Jun; 219():40-48. PubMed ID: 29778203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.